TNYA -
Tenaya Therapeutics, Inc. Common Stock
Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
2.0 -0.09 (-4.5%) |
--- |
-0.02 (-1.04%) |
-0.02 (-1.04%) |
0.04 (2.0%) |
-0.13 (-6.65%) |
0.02 (1.05%) |
0.02 (1.05%) |
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
Earnings & Ratios
- Basic EPS:
- -0.14
- Diluted EPS:
- -0.14
- Basic P/E:
- -13.6429
- Diluted P/E:
- -13.6429
- RSI(14) 1m:
- 33.5
- VWAP:
- 1.92
- RVol:
Events
Period |
Kind |
Movement |
Occurred At |
Related News
Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025
Aug 31, 2025 14:15
2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies
Mar 04, 2025 15:55
Tenaya Therapeutics Announces Research Leadership Updates
Jun 27, 2024 21:00
Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit
Jun 18, 2024 20:30
Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 20:05
Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting
May 02, 2024 21:00
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Mar 18, 2024 20:05
Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine
Mar 18, 2024 12:30
Blend Labs Reports Q4 Results, Joins Alta Equipment, Despegar.com And Other Big Stocks Moving Higher On Friday
Mar 15, 2024 14:25
Tenaya Therapeutics to Participate in Upcoming March Investor Conferences
Feb 27, 2024 21:30